This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS | MicrobiomeTrials
← Back to trials NCT07439510
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS Recruiting PHASE2, PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-12-01Est. Completion: 2030-02-01
Enrollment target: 120 participantsOther microbiome trials you might be interested in Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including Sickle Cell Disease Cystic Fibrosis Fragile X Syndrome Proximal Spinal Muscular Atrophy Myotonic Dystrophy Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker Neurofibromatosis-Noonan Syndrome Huntington Disease Hemophilia A Hemophilia B MODY2 Diabetes X-Linked Hydrocephalus Autosomal Recessive Polycystic Kidney Disease
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5…
Paris, France Est. completion May 2027
Genetic Disorder Asperger Disorder Autism Spectrum Disorder Fragile X Syndrome Developmental Delay
Background: Some patients with unusual genetic conditions are referred to the National Institutes of Health (NIH). They …
Bethesda, United States Completed Jul 8, 2025